Search | Clinical Trials Finder

Conditions: Heart Defects, Congenital
Interventions: Clopidogrel, placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 12 Months and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Neonatal Resuscitation
Interventions: Non-inflatable supraglottic airway, Face Mask, T-Piece Resuscitator; Device
Lead sponsor: University of Oklahoma; Other
Eligibility: Up to 30 Minutes
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation
Interventions: Lumacaftor Plus Ivacaftor Combination, Ivacaftor; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 12 Years and older
Enrollment: 1,164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 91
States / cities: Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 88 more

Conditions: Preterm Less Than 32wks With IVH, WMI/PVL, Late Preterm or Term (37-42wks) With Neonatal Encephalopathy Treated With Hypothermia for HIE
Interventions: Prospective Clinical and Neurodevelopmental Data Collection; Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 31 Weeks to 42 Weeks
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Cystic Fibrosis
Interventions: TEZ/IVA, IVA; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 12 Years and older
Enrollment: 1,131 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 69
States / cities: Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 66 more

Conditions: Premature Birth
Interventions: Family Nurture Intervention; Behavioral
Lead sponsor: Columbia University; Other
Eligibility: 26 Weeks to 34 Weeks
Enrollment: 394 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2018
U.S. locations: 1
States / cities: New York, New York

Conditions: Cystic Fibrosis
Interventions: ELX/TEZ/IVA, IVA; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 12 Years and older
Enrollment: 458 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 46
States / cities: Birmingham, Alabama • Palo Alto, California • Aurora, Colorado + 42 more

Conditions: Meconium Aspiration
Interventions: Lucinactant, Standard Care; Drug · Other
Lead sponsor: Windtree Therapeutics; Industry
Eligibility: Up to 48 Hours
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2004
U.S. locations: 1
States / cities: Warrington, Pennsylvania

Conditions: Retinopathy of Prematurity (ROP)
Interventions: rhIGF-1/rhIGFBP-3; Drug
Lead sponsor: Shire; Industry
Eligibility: 40 Weeks to 108 Weeks
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 4
States / cities: Mobile, Alabama • Greenville, North Carolina • Oklahoma City, Oklahoma + 1 more

Conditions: Anemia
Interventions: Umbilical Cord Milking; Other
Lead sponsor: University of Rhode Island; Other
Eligibility: 18 Years to 44 Years · Female only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Neonates
Interventions: Not listed
Lead sponsor: GE Healthcare; Industry
Eligibility: 23 Weeks to 6 Months
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: San Diego, California

Conditions: Hunter Syndrome, Mucopolysaccharidosis II (MPS II)
Interventions: Idursulfase; Biological
Lead sponsor: Shire; Industry
Eligibility: 5 Years and older · Male only
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 16
States / cities: Phoenix, Arizona • Oakland, California • Denver, Colorado + 13 more

Conditions: Persistent Fetal Circulation Syndrome, Hypertension, Pulmonary, of Newborn, Persistent, Persistent Pulmonary Hypertension of Newborn
Interventions: Inhaled nitric oxide, Nitrogen Gas, Crossover iNO; Drug
Lead sponsor: University of Florida; Other
Eligibility: 30 Minutes to 48 Hours
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: ABO Incompatibility, Hemolytic Disease of Newborn, Neonatal Jaundice, Neonatal Hyperbilirubinemia
Interventions: Not listed
Lead sponsor: State University of New York - Upstate Medical University; Other
Eligibility: Up to 28 Days
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 2
States / cities: Syracuse, New York

Conditions: Pulmonary Hypertension
Interventions: Inhaled Iloprost; Drug
Lead sponsor: University of Chicago; Other
Eligibility: Up to 7 Days
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Infant, Newborn, Hypotension, Blood Pressure
Interventions: Not listed
Lead sponsor: NICHD Neonatal Research Network; Network
Eligibility: Up to 72 Hours
Enrollment: 820 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 17
States / cities: Birmingham, Alabama • Palo Alto, California • New Haven, Connecticut + 13 more

Conditions: Cystic Fibrosis
Interventions: LUM/IVA; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 6 Years and older
Enrollment: 246 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 37
States / cities: Birmingham, Alabama • Tucson, Arizona • Long Beach, California + 34 more

Conditions: Cystic Fibrosis
Interventions: inhaled mannitol, Placebo comparator; Drug
Lead sponsor: Syntara; Industry
Eligibility: 6 Years and older
Enrollment: 318 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 28
States / cities: Tucson, Arizona • Hartford, Connecticut • Jacksonville, Florida + 23 more

Conditions: Hypoxic-Ischemic Encephalopathy
Interventions: RLS-0071, Placebo; Drug
Lead sponsor: ReAlta Life Sciences, Inc.; Industry
Eligibility: Up to 10 Hours
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 15
States / cities: Little Rock, Arkansas • Orange, California • San Diego, California + 11 more

Conditions: Lipid Metabolism, Inborn Errors, Hypercholesterolemia, Autosomal Dominant, Hyperlipidemias, Metabolic Diseases, Hyperlipoproteinemia Type II, Metabolism, Inborn Errors, Genetic Diseases, Inborn, Infant, Newborn, Diseases, Metabolic Disorder, Congenital Abnormalities, Hypercholesterolemia, Hyperlipoproteinemias, Dyslipidemias, Lipid Metabolism Disorders
Interventions: Mipomersen Sodium; Drug
Lead sponsor: Kastle Therapeutics, LLC; Industry
Eligibility: 12 Years and older
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 20
States / cities: Mission Viejo, California • Newport Beach, California • Bridgeport, Connecticut + 17 more

Conditions: Congenital Diaphragmatic Hernia
Interventions: BALT GOLDBAL2 Balloon; Device
Lead sponsor: Inna Lobeck; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2032
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Cystic Fibrosis
Interventions: IVA; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 0 Months to 24 Months
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 17
States / cities: Birmingham, Alabama • Palo Alto, California • Wilmington, Delaware + 14 more

Conditions: Retinopathy of Prematurity
Interventions: Non-Interventional; Other
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 11 Months to 5 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 9
States / cities: La Jolla, California • Loma Linda, California • San Francisco, California + 5 more

Conditions: Infant, Newborn, Hypertension, Pulmonary, Persistent Fetal Circulation Syndrome, Pneumonia, Aspiration, Respiratory Distress Syndrome, Newborn, Respiratory Insufficiency
Interventions: Inhaled Nitric Oxide, Standard iNO therapy; Drug
Lead sponsor: NICHD Neonatal Research Network; Network
Eligibility: Up to 14 Days
Enrollment: 302 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2003
U.S. locations: 18
States / cities: Birmingham, Alabama • Phoenix, Arizona • Palo Alto, California + 14 more

Search by objective public record fields.

Long Term Safety of Clopidogrel in Neonates/Infants With Systemic to Pulmonary Artery Shunt Palliation

Non-inflatable Supraglottic Airway (NI-SGA) vs. Face Mask (FM) as a Primary Interface Device for Neonatal Resuscitation

A Phase 3 Rollover Study of Lumacaftor in Combination With Ivacaftor in Subjects 12 Years and Older With Cystic Fibrosis

Cerebral/ Cortical Visual Impairment: Screening, Identification and Outcome Prediction in Neonates

A Study to Evaluate the Safety and Efficacy of Long Term Treatment With VX-661 in Combination With Ivacaftor in Participants With Cystic Fibrosis Who Have an F508del-CFTR Mutation

Family Nurture Intervention (FNI) in Neonatal Intensive Care Unit (NICU)

A Study Evaluating the Long-term Safety of VX-445 Combination Therapy

Phase III Randomized Study of Lucinactant in Full Term Newborn Infants With Meconium Aspiration Syndrome

Long-term Safety and Efficacy Outcome Study Comparing Children Previously Enrolled in Study ROPP-2008-01 for the Prevention of Retinopathy of Prematurity (ROP)

Milking the Umbilical Cord at Term Cesarean Birth

NICU-TECH RM9L-RS Probe ME Feasibility Study

Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Idursulfase

Early iNO for Oxidative Stress, Vascular Tone and Inflammation in Babies With Hypoxic Respiratory Failure

Measurement of Carboxyhemoglobin by Gas Chromatography as an Index of Hemolysis

Inhaled Iloprost for the Treatment of Persistent Pulmonary Hypertension in the Term and Near Term Infants.

Hypotension in Neonates

Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Lumacaftor in Combination With Ivacaftor

Long Term Administration of Inhaled Mannitol in Cystic Fibrosis

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of RLS-0071 in Newborns With Moderate or Severe Hypoxic-Ischemic Encephalopathy Undergoing Therapeutic Hypothermia

An Open-label Extension Study to Assess the Long-term Safety and Efficacy of ISIS 301012 (Mipomersen) in Patients With Familial Hypercholesterolemia or Severe-Hypercholesterolemia

Infant Survival and Long-term Outcome Following Fetoscopic Endoluminal Tracheal Occlusion in Severe Left and Right Congenital Diaphragmatic Hernia, A Phase III Trial

A Study to Evaluate the Safety of Long-term Ivacaftor Treatment in Participants With Cystic Fibrosis Who Are Less Than 24 Months of Age at Treatment Initiation and Have an Approved Ivacaftor-Responsive Mutation

Extension Study to Evaluate the Long-Term Outcomes of Pediatric Patients Who Received Treatment for Retinopathy of Prematurity in the VGFTe-ROP-1920 Study (Acronym: Butterfleye Next)

Early Inhaled Nitric Oxide for Respiratory Failure in Newborns